Valencia, Spain

Raúl Blasco

This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignees: Fibrostein, S.l., University of Valencia. Active years: 2015.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Raúl Blasco. Retrieved from https://idiyas.com/inventor/raúl-blasco

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 1 

% Patents Active = 100.0

Average Co-Inventor Count = 8.0

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 2015

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Raúl Blasco: Innovator in Cancer Treatment

Introduction

Raúl Blasco is a notable inventor based in Valencia, Spain. He has made significant contributions to the field of cancer treatment through his innovative research and patents. His work focuses on the therapeutic use of specific inhibitors that target cancer cells.

Latest Patents

Raúl Blasco holds a patent for "GPBP-1 inhibition and its therapeutic use." This invention provides compositions that include anti-tumor agents and inhibitors of Goodpasture antigen binding protein, p21, and ABCC7. These compositions are designed for use in treating cancer, showcasing his commitment to advancing medical science.

Career Highlights

Throughout his career, Raúl has worked with various organizations, including Fibrostein, S.L. and Universitat de València. His experience in these institutions has allowed him to develop and refine his innovative ideas, contributing to the scientific community.

Collaborations

Raúl has collaborated with notable colleagues such as Juan Saus and Francisco Revert-Ros. These partnerships have enriched his research and expanded the impact of his inventions.

Conclusion

Raúl Blasco is a dedicated inventor whose work in cancer treatment exemplifies the importance of innovation in medicine. His patent and collaborations reflect his commitment to improving therapeutic options for patients.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…